Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Accumulated Expenses (2023 - 2025)

Rallybio's Accumulated Expenses history spans 3 years, with the latest figure at $4.2 million for Q2 2025.

  • For Q2 2025, Accumulated Expenses changed N/A year-over-year to $4.2 million; the TTM value through Jun 2025 reached $4.2 million, changed N/A, while the annual FY2024 figure was $5.0 million, 38.5% down from the prior year.
  • Accumulated Expenses for Q2 2025 was $4.2 million at Rallybio, down from $5.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8.1 million in Q4 2023 and bottomed at $4.2 million in Q2 2025.
  • The 3-year median for Accumulated Expenses is $5.6 million (2024), against an average of $5.9 million.
  • The largest YoY upside for Accumulated Expenses was 38.5% in 2024 against a maximum downside of 38.5% in 2024.
  • A 3-year view of Accumulated Expenses shows it stood at $8.1 million in 2023, then plummeted by 38.5% to $5.0 million in 2024, then fell by 14.83% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for RLYB's Accumulated Expenses are $4.2 million (Q2 2025), $5.0 million (Q4 2024), and $6.3 million (Q3 2024).